Jeff Yass’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-332,100
| Closed | -$116K | – | 10658 |
|
|
2016
Q3 | $116K | Sell |
332,100
-245,300
| -42% | -$85.7K | ﹤0.01% | 7883 |
|
|
2016
Q2 | $269K | Buy |
577,400
+305,600
| +112% | +$142K | ﹤0.01% | 7137 |
|
|
2016
Q1 | $370K | Sell |
271,800
-147,600
| -35% | -$201K | ﹤0.01% | 6909 |
|
|
2015
Q4 | $617K | Sell |
419,400
-305,800
| -42% | -$450K | ﹤0.01% | 6365 |
|
|
2015
Q3 | $1.15M | Sell |
725,200
-481,100
| -40% | -$760K | ﹤0.01% | 5444 |
|
|
2015
Q2 | $2.05M | Sell |
1,206,300
-13,600
| -1% | -$23.1K | ﹤0.01% | 4667 |
|
|
2015
Q1 | $1.7M | Sell |
1,219,900
-23,900
| -2% | -$33.2K | ﹤0.01% | 4637 |
|
|
2014
Q4 | $1.88M | Buy |
1,243,800
+157,500
| +14% | +$238K | ﹤0.01% | 4573 |
|
|
2014
Q3 | $2.24M | Sell |
1,086,300
-184,900
| -15% | -$381K | ﹤0.01% | 4399 |
|
|
2014
Q2 | $3.89M | Buy |
1,271,200
+488,100
| +62% | +$1.49M | ﹤0.01% | 3493 |
|
|
2014
Q1 | $1.96M | Buy |
783,100
+360,000
| +85% | +$900K | ﹤0.01% | 4398 |
|
|
2013
Q4 | $2.1M | Buy |
423,100
+37,800
| +10% | +$188K | ﹤0.01% | 4189 |
|
|
2013
Q3 | $875K | Buy |
385,300
+210,200
| +120% | +$477K | ﹤0.01% | 5515 |
|
|
2013
Q2 | $389K | Buy |
+175,100
| New | +$389K | ﹤0.01% | 6408 |
|
Jeff Yass's RXII Position: Q4 2016 in Review
Jeff Yass sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 535,907 shares — an estimated $188K sold.
Jeff Yass first reported a position in RXII in Q3 2013 and held it in 13 quarters. The position peaked at $1.78M in Q2 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Jeff Yass reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Jeff Yass sold 535,907 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $188K.
- Jeff Yass first reported a position in GALENA BIOPHARMA INC COM in Q3 2013 and held it in 13 quarters.
- Jeff Yass's GALENA BIOPHARMA INC COM position peaked at $1.78M in Q2 2014.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Susquehanna International Group's 13F filing for Q4 2016, filed 14 Feb 2017.